2-甲基-5-((3-(三氟甲基)苯基)氨基甲酰基)苯甲酸 | 1018069-85-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-甲基-5-((3-(三氟甲基)苯基)氨基甲酰基)苯甲酸
• 英文名称: 2-methyl-5-((3-(trifluoromethyl)phenyl)carbamoyl)benzoic acid
• 英文别名: 2-Methyl-5-(3-(trifluoromethyl)phenylcarbamoyl)benzoic acid；2-methyl-5-[[3-(trifluoromethyl)phenyl]carbamoyl]benzoic acid
• CAS: 1018069-85-6
• 化学式: C₁₆H₁₂F₃NO₃
• 分子量: 323.271
• InChiKey: FDQNGMZKIUOERJ-UHFFFAOYSA-N

物化性质

• 沸点：
  389.8±42.0 °C(Predicted)
• 密度：
  1.401±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2,5-二氨基嘧啶 、 2-甲基-5-((3-(三氟甲基)苯基)氨基甲酰基)苯甲酸 在 三乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 N3-(2-amino-5-pyrimidinyl)-4-methyl-N1-(3-(trifluoromethyl)phenyl)-1,3-benzenedicarboxamide
  参考文献：
  名称：

  Discovery of a potent and selective c-Kit inhibitor for the treatment of inflammatory diseases

  摘要：

  A potent and selective c-Kit inhibitor 20 was identified through a structure-activity relationship study. In an in vivo mouse model of mast cell activation, 20 blocked the SCF-induced histamine release with an EC(50) of 26 nM. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.05.089
• 作为产物：
  描述：

  2-甲基-5-((3-(三氟甲基)苯基)氨基甲酰基)苯甲酸甲酯 在 lithium hydroxide 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 20.0h， 以92%的产率得到2-甲基-5-((3-(三氟甲基)苯基)氨基甲酰基)苯甲酸
  参考文献：
  名称：

  Structure-Guided Design of Aminopyrimidine Amides as Potent, Selective Inhibitors of Lymphocyte Specific Kinase: Synthesis, Structure–Activity Relationships, and Inhibition of in Vivo T Cell Activation

  摘要：

  The lymphocyte-specific kinase (Lck), a member of the Src family of cytoplasmic tyrosine kinases, is expressed in T cells and natural killer (NK) cells. Genetic evidence, including knockout mice and human mutations, demonstrates that Lck kinase activity is critical for normal T cell development, activation, and signaling. Selective inhibition of Lck is expected to offer a new therapy for the treatment of T-cell-mediated autoimmune and inflammatory disease. With the aid of X-ray structure-based analysis, aminopyrimidine amides 2 and 3 were designed from aminoquinazolines 1, which had previously been demonstrated to exhibit potent inhibition of Lck and T cell proliferation. In this report, we describe the synthesis and structure-activity relationships of a series of novel aminopyrimidine amides 3 possessing improved cellular potency and selectivity profiles relative to their aminoquinazoline predecessors 1. Orally bioavailable compound 13b inhibited the anti-CD3-induced production of interleukin-2 (IL-2) in mice in a dose-dependent manner (ED50 = 9.4 mg/kg).

  DOI：

  10.1021/jm7010996

文献信息

• Discovery of a Series of 2,5-Diaminopyrimidine Covalent Irreversible Inhibitors of Bruton’s Tyrosine Kinase with in Vivo Antitumor Activity
  作者：Xitao Li、Yingying Zuo、Guanghui Tang、Yan Wang、Yiqing Zhou、Xueying Wang、Tianlin Guo、Mengying Xia、Ning Ding、Zhengying Pan

  DOI：10.1021/jm4017762

  日期：2014.6.26

  Bruton’s tyrosine kinase (Btk) is an attractive drug target for treating several B-cell lineage cancers. Ibrutinib is a first-in-class covalent irreversible Btk inhibitor and has demonstrated impressive effects in multiple clinical trials. Herein, we present a series of novel 2,5-diaminopyrimidine covalent irreversible inhibitors of Btk. Compared with ibrutinib, these inhibitors exhibited a different

  Bruton的酪氨酸激酶（Btk）是治疗几种B细胞谱系癌症的引人注目的药物靶标。依鲁替尼是一流的共价不可逆Btk抑制剂，在多项临床试验中已显示出令人印象深刻的效果。在本文中，我们介绍了一系列新型的Btk 2，5-二氨基嘧啶共价不可逆抑制剂。与依鲁替尼相比，这些抑制剂对所分析的激酶表现出不同的选择性，并具有抑制Btk活化和催化活性的双重作用模式，从而抵消了Btk的负调节回路。该系列中的两种化合物31和38，显示出对多种B细胞淋巴瘤细胞系的有效抗增殖活性，包括生发中心B细胞样弥散性大B细胞淋巴瘤（GCB-DLBCL）细胞。另外，化合物31在小鼠异种移植模型中显着阻止了肿瘤的生长。
• KINASE INHIBITOR AND METHOD FOR TREATMENT OF RELATED DISEASES
  申请人：Peking University Shenzhen Graduate School

  公开号：EP2772486A1

  公开（公告）日：2014-09-03

  Disclosed is a compound of (aminophenylamino) pyrimidyl benzamides and a synthesis method thereof. The compound has Btk-inhibition activity and can be used to treat autoimmune diseases, heteroimmune diseases, cancers or thromboembolic diseases.

  本发明公开了一种（氨基苯氨基）嘧啶基苯甲酰胺化合物及其合成方法。该化合物具有 Btk 抑制活性，可用于治疗自身免疫性疾病、异种免疫性疾病、癌症或血栓栓塞性疾病。
• Discovery of a potent and selective c-Kit inhibitor for the treatment of inflammatory diseases
  作者：Ning Chen、Roland W. Bürli、Susana Neira、Randall Hungate、Dawei Zhang、Violeta Yu、Yen Nguyen、Yanyan Tudor、Matthew Plant、Shaun Flynn、Kristin L. Meagher、Matthew R. Lee、Xuxia Zhang、Andrea Itano、Michael Schrag、Yang Xu、Gordon Y. Ng、Essa Hu

  DOI：10.1016/j.bmcl.2008.05.089

  日期：2008.7

  A potent and selective c-Kit inhibitor 20 was identified through a structure-activity relationship study. In an in vivo mouse model of mast cell activation, 20 blocked the SCF-induced histamine release with an EC(50) of 26 nM. (c) 2008 Elsevier Ltd. All rights reserved.
• EP2772486B1
  申请人：——

  公开号：EP2772486B1

  公开（公告）日：2016-03-16
• US20140256759A1
  申请人：——

  公开号：US20140256759A1

  公开（公告）日：2014-09-11